Ulisse Biomed S.p.A. (UBM.MI)
Ulisse Biomed S.p.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Udine, UD, IT. The stock last traded at $0.81, up 0.00% on the session, giving a market capitalisation of $19.6M. Its beta of 0.80 implies it has historically moved less than the broad market.
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Ulisse Biomed S.p.A. is most often compared with the following Healthcare names: